HC Wainwright & Co. Reiterates Buy on NeuroPace, Maintains $20 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 84.2%

Neg 0% Neu 84.2% Pos 0%

HC Wainwright & Co. analyst Yi Chen reiterates NeuroPace (NASDAQ:NPCE) with a Buy and maintains $20 price target.

Comments

No comments yet. Be the first!